Andromeda Metals Limited

ASX:ADN Rapport sur les actions

Capitalisation boursière : AU$49.7m

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Andromeda Metals Croissance future

Future contrôle des critères 0/6

Andromeda Metals is forecast to grow earnings and revenue by 67% and 149.3% per annum respectively while EPS is expected to grow by 72.2% per annum.

Informations clés

67.0%

Taux de croissance des bénéfices

72.2%

Taux de croissance du BPA

Metals and Mining croissance des bénéfices14.4%
Taux de croissance des recettes149.3%
Rendement futur des capitaux propresn/a
Couverture par les analystes

Low

Dernière mise à jour28 Jul 2024

Mises à jour récentes de la croissance future

Recent updates

We Think Andromeda Metals (ASX:ADN) Needs To Drive Business Growth Carefully

Aug 25
We Think Andromeda Metals (ASX:ADN) Needs To Drive Business Growth Carefully

We Think Andromeda Metals (ASX:ADN) Needs To Drive Business Growth Carefully

Mar 14
We Think Andromeda Metals (ASX:ADN) Needs To Drive Business Growth Carefully

Andromeda Metals Limited (ASX:ADN): Are Analysts Optimistic?

Jan 20
Andromeda Metals Limited (ASX:ADN): Are Analysts Optimistic?

Prévisions de croissance des bénéfices et des revenus

ASX:ADN - Estimations futures des analystes et données financières antérieures (AUD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
6/30/2026414-1881
6/30/2025N/A-8-90-41
6/30/2024N/A-7-9-61
12/31/2023N/A-10-16-8N/A
9/30/2023N/A-10-17-9N/A
6/30/2023N/A-9-18-9N/A
3/31/2023N/A-9-16-8N/A
12/31/2022N/A-9-14-7N/A
9/30/2022N/A-9-12-6N/A
6/30/2022N/A-9-10-5N/A
3/31/2022N/A-8-10-4N/A
12/31/2021N/A-8-9-4N/A
9/30/2021N/A-7-8-3N/A
6/30/2021N/A-6-7-2N/A
3/31/2021N/A-5-7-2N/A
12/31/2020N/A-4-6-2N/A
9/30/2020N/A-4-5-1N/A
6/30/2020N/A-3-4-1N/A
3/31/20200-3-3-1N/A
12/31/20190-3-2-1N/A
9/30/20190-2-2-1N/A
6/30/2019N/A-1-2-1N/A
3/31/20190-1-2-1N/A
12/31/20180-1-2-1N/A
9/30/20180-1-2-1N/A
6/30/20180-1-1-1N/A
3/31/20180-2-1-1N/A
12/31/20170-3-1-1N/A
9/30/20170-5N/A-1N/A
6/30/2017N/A-7N/A-1N/A
3/31/2017N/A-7N/A-1N/A
12/31/2016N/A-7N/A-1N/A
9/30/2016N/A-5N/A-1N/A
6/30/2016N/A-4N/A-1N/A
3/31/20160-3N/A-1N/A
12/31/20150-1N/A-1N/A
9/30/20150-1N/A-1N/A
6/30/20150-1N/A-1N/A
3/31/20150-4N/A-1N/A
12/31/20140-7N/A-1N/A
9/30/20140-7N/A-1N/A
6/30/20140-7N/A-1N/A
3/31/20140-4N/A-1N/A
12/31/20130-1N/A-1N/A
9/30/20130-4N/A-1N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: ADN is forecast to remain unprofitable over the next 3 years.

Bénéfices vs marché: ADN is forecast to remain unprofitable over the next 3 years.

Croissance élevée des bénéfices: ADN is forecast to remain unprofitable over the next 3 years.

Chiffre d'affaires vs marché: ADN is forecast to have no revenue next year.

Croissance élevée des revenus: ADN is forecast to have no revenue next year.


Prévisions de croissance du bénéfice par action


Rendement futur des capitaux propres

ROE futur: Insufficient data to determine if ADN's Return on Equity is forecast to be high in 3 years time


Découvrir les entreprises en croissance